| pubmed-article:15448029 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15448029 | lifeskim:mentions | umls-concept:C0007134 | lld:lifeskim |
| pubmed-article:15448029 | lifeskim:mentions | umls-concept:C0439640 | lld:lifeskim |
| pubmed-article:15448029 | lifeskim:mentions | umls-concept:C0042210 | lld:lifeskim |
| pubmed-article:15448029 | lifeskim:mentions | umls-concept:C0332466 | lld:lifeskim |
| pubmed-article:15448029 | pubmed:issue | 18 Pt 2 | lld:pubmed |
| pubmed-article:15448029 | pubmed:dateCreated | 2004-9-27 | lld:pubmed |
| pubmed-article:15448029 | pubmed:abstractText | Renal cell carcinoma is a malignant disease that demonstrates resistance to standard chemotherapeutic agents. A promising area of investigation is the use of cancer vaccines to educate host immunity to specifically target and eliminate malignant cells. Dendritic cells (DCs) are potent antigen-presenting cells that are uniquely effective in generating primary immune responses. DCs that are manipulated to present tumor antigens induce antitumor immunity in animal models and preclinical human studies. A myriad of strategies have been developed to effectively load tumor antigen onto DCs, including the introduction of individual peptides, proteins, or tumor-specific genes, as well as the use of whole tumor cells as a source of antigen. A promising approach for the design of cancer vaccines involves the fusion of whole tumor cells with DCs. The DC-tumor fusion presents a spectrum of tumor-associated antigens to helper and cytotoxic T-cell populations in the context of DC-mediated costimulatory signals. In animal models, vaccination with DC-tumor fusions resulted in protection from tumor challenge and regression of established metastatic disease. We have conducted phase 1 dose escalation studies in which patients with metastatic breast and renal cancer underwent vaccination with DC-tumor fusions. Twenty-three patients underwent vaccination with autologous DC-tumor fusions. Vaccination was well tolerated without substantial treatment-related toxic effects. Immunologic responses and disease regression were observed in a subset of patients. Future studies will explore the effect of DC maturation and cytokine adjuvants on vaccine potency. | lld:pubmed |
| pubmed-article:15448029 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15448029 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15448029 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15448029 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:15448029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15448029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15448029 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15448029 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15448029 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:15448029 | pubmed:issn | 1078-0432 | lld:pubmed |
| pubmed-article:15448029 | pubmed:author | pubmed-author:AviganDavidD | lld:pubmed |
| pubmed-article:15448029 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15448029 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:15448029 | pubmed:volume | 10 | lld:pubmed |
| pubmed-article:15448029 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15448029 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15448029 | pubmed:pagination | 6347S-52S | lld:pubmed |
| pubmed-article:15448029 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:meshHeading | pubmed-meshheading:15448029... | lld:pubmed |
| pubmed-article:15448029 | pubmed:year | 2004 | lld:pubmed |
| pubmed-article:15448029 | pubmed:articleTitle | Dendritic cell-tumor fusion vaccines for renal cell carcinoma. | lld:pubmed |
| pubmed-article:15448029 | pubmed:affiliation | Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. davigan@caregroup.harvard.edu | lld:pubmed |
| pubmed-article:15448029 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15448029 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:15448029 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15448029 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15448029 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15448029 | lld:pubmed |
